

**Question for written answer E-003921/2026
to the Commission**
Rule 144
Martin Häusling (Verts/ALE)

Subject: Herbal veterinary medicine(s): avoiding a regulatory gap and ensuring continued availability after 29 January 2027

Regulation 2019/6 creates a striking regulatory gap for traditional herbal veterinary medicinal products (HVMPs). Article 157 requires the Commission to report, by 29 January 2027, on traditional herbal products used to treat animals in the Union and, if appropriate, propose a simplified registration system. Standard authorisation requirements, geared towards synthetic, highly effective single substances, are disproportionate for HVMPs and may significantly reduce their availability. On the other hand, there is a demand for herbal products among animal keepers, HVMPs have the potential to reduce veterinary use of antimicrobials, and Regulation 889/2008 requires the use of HVMPs as first line treatment for organic farm animals.

Article 152(2) prohibits veterinary medicinal products, including HVMPs, placed on the market under the previous legislation from remaining available after 29 January 2027. Consequently, such HVMPs may lose market access before the regulatory solution envisaged by Article 157 can be adopted and implemented.

1. How does the Commission intend to prevent HVMPs with market access under Article 152(2) from losing market access on 29 January 2027?
2. The Commission has commissioned a consultant to collect the information required under Article 157. Has this study been delivered, and will the Commission publish it? If so, when?
3. What concrete measures will the Commission take to ensure the continued and improved availability of HVMPs or other herbal medicinal products through veterinarians?

Submitted: 29.9.2026